Categories Earnings, Health Care

Sanofi (NASDAQ: SNY): Q3 2019 Earnings Snapshot

— Generic drugmaker Sanofi (NASDAQ: SNY) reported net income of EUR 1.77 billion or EUR 1.49 per share for the third quarter, on IFRS basis, down 23.% and 18.6% respectively from last year

— IFRS net sales increased 1.1% year-over-year to EUR 9.5 billion, on a reported basis

— Sanofi Genzyme sales rose 19.5% annually, aided by continued strong uptake of Dupixent

— Vaccine sales decreased 9.8%, reflecting anticipated weighing of flu vaccine supply towards year-end

— Expects business earnings to grow about 5%, on a constant-currency basis and excluding one-off items, in fiscal 2019

— During the quarter, European Commission approved Dupixent for severe chronic rhinosinusitis

— Achieved positive results from advanced-stage study on Dupixent for severe atopic dermatitis in children

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

Most Popular

CVX Earnings: Chevron reports lower revenue and profit for Q3 2024

Energy exploration company Chevron Corporation (NYSE: CVX) on Friday announced third-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation dropped to

Key highlights from Exxon Mobil Corporation’s (XOM) Q3 2024 earnings results

Exxon Mobil Corporation (NYSE: XOM) reported its third quarter 2024 earnings results today. Total revenues and other income remained relatively flat at $90 billion compared to the same period a

AAPL Earnings: Apple Q4 2024 sales rise 6% YoY, beat estimates

Apple Inc. (NASDAQ: AAPL) reported an increase in revenues for the fourth quarter of 2024. The top line came in above estimates. The gadget giant generated revenues of $94.9 billion

Comments

  1. Pingback: itme.xyz
  2. Pingback: ItMe.Xyz
  3. Pingback: ItMe.Xyz
  4. Pingback: MasumINTL
  5. Pingback: ItMe.Xyz
  6. Pingback: FB URL Shortener

Comments are closed.

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top